Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096) fair value: what the stock is really worth
As of Sep 22, 2026: fair value of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. ¥13.18, price ¥50.20, upside -73.8%, quality 44 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
57‑month range ¥31.87 – ¥98.58 · fair‑value band ¥8.95 – ¥17.40 · the ¥50.20 price screens above the ¥13.18 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. in your weekly email
Every Wednesday you see whether Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. operates as a pharmaceutical technology research and development and services company in China.
Show more
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. operates as a pharmaceutical technology research and development and services company in China. The company primarily provides drug research and development services; and the transformation of research and development technology results for various pharmaceutical, as well as pharmaceutical research and development investment companies. Its business covers the principal links of drug discovery, pharmaceutical research, clinical trials, customized research and development and production, and registration applications. The company was incorporated in 2011 and is headquartered in Hangzhou, China.
Stock analysis
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096) currently trades at ¥50.20, while our model-based Fair Value estimate is ¥13.18, implying the stock looks roughly 281.0% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 2 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: ¥8.95 (bear) to ¥17.40 (bull), the price of ¥50.20 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. reported revenue of 678M CNY in FY2025 versus 374M CNY in FY2021, a compound +16.0%/yr. Reported net income was −90.4M CNY in FY2025.
Key figures
Market cap 6.0B CNY (≈ $895M) · P/S ratio 8.44 · EPS (TTM) ¥−0.4700 · Dividend yield 0.3% · Net margin −13.3% · Return on equity −2.0% · Return on assets (EBIT) 3.5% · Operating margin 7.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).
What moves the price
The share trades about 27% below its 52-week high and 40% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −2% fair-value upside, at −74%, 301096 screens richer than that median.
Fair Value models
Bear ¥8.95Fair Value ¥13.18Bull ¥17.40
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−15.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+26.7%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.7%
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
31.8% (2020) → −3.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 73 stocks
Beats the industry median on 5/11 measures
A mixed picture versus its industry peers.
Valuation
Quality Score46 · Bottom 25%
Fair Value upside−74% · Bottom 25%
Profitability
Return on assets−1% · Bottom 25%
Net margin (TTM)−7% · Bottom 25%
Operating margin (TTM)7% · Below median
Growth and dividend
Revenue growth25% · Top 25%
Dividend yield (TTM)0.3% · Bottom 25%
Balance sheet
Debt / equity0.08× · Below median
Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper
P/B0.36× · Cheapest 25%
P/S (TTM)1.26× · Cheapest 25%
EV/EBITDA6.9× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 18
FUTURE (revenue growth)100· sector 29
PAST (return on equity)0· sector 52
HEALTH (low debt)96· sector 94
DIVIDEND (yield)7· sector 42
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ¥13.18 versus a price of ¥50.20, about −74% upside (overvalued).
What is the fair value of 301096?
Our model-based fair value for Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. is ¥13.18 (as of Sep 24, 2026), built from audited fundamentals. The current price: ¥50.20.
What is the quality score of 301096?
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096)?
Our model-based price target is the fair value of ¥13.18 (as of Sep 24, 2026) from 2 valuation models. Cautious scenario ¥8.95, optimistic scenario ¥17.40. It is a calculation from audited fundamentals, not an analyst target.
What is the Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. stock forecast for 2026?
Our models put fair value at ¥13.18, about −74% upside versus a price of ¥50.20 (overvalued). Cautious scenario ¥8.95, optimistic scenario ¥17.40. The calculation is refreshed regularly with new filings.
What is the revenue of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096)?
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. reported trailing-twelve-month revenue of about 710M CNY (latest available figure, as of Sep 24, 2026).
Does Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. pay a dividend?
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. currently shows a dividend yield of about 0.34% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. it is ¥13.18 per share (as of Sep 24, 2026), against a price of ¥50.20. It is the blended result of 2 valuation models (cash flow, earnings, asset, dividend).
Is Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 301096 trades above its calculated fair value: price ¥50.20, fair value ¥13.18, a gap of about −74% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 301096?
No. The price is what the market pays today (¥50.20); the fair value is what the company's own numbers justify (¥13.18). For Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. the two are ¥37.02 per share apart. That gap is exactly why we show both numbers side by side.
How much is Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. worth?
The market values Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. at about 6.0B CNY (market capitalisation, as of Sep 24, 2026). Per share that is ¥50.20; our models calculate a fair value of ¥13.18 per share.
What do the bullish and bearish scenarios say about 301096?
Our models span a range for Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.: cautious scenario ¥8.95, base ¥13.18, optimistic ¥17.40 per share (as of Sep 24, 2026, price ¥50.20). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096)?
Balance-sheet figures for Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (as of Sep 24, 2026): return on equity −2.0%, debt of 0.08 per unit of equity. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is 301096 from its 52-week high?
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. trades at ¥50.20, about 27% below its 52-week high of ¥68.99 and 40% above the low of ¥35.96 (as of Sep 22, 2026). Distance from the high says nothing about value: that is what the fair value of ¥13.18 is for.
Which stocks are comparable to Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. stock attractive at the current price?
The data as of Sep 24, 2026: price ¥50.20, calculated fair value ¥13.18 (−74%), Quality Score 44/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 301096 calculated?
We run Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. through 2 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥13.18, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096)?
The closing price on Sep 22, 2026 was ¥50.20. Our model-based fair value is ¥13.18, about −74% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. right now?
The price sits above even our optimistic bull case (¥17.40). The favourable scenario is already priced in. Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (¥8.95 to ¥17.40) leaves room in how you read the outcome.
Key figures of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.
How large is the market capitalisation of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096)?
The market capitalisation of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. is 6.0B CNY (≈ $895M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096)?
The price-to-sales ratio of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. is 8.44 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096)?
Earnings per share at Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. are ¥−0.4700. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096)?
The dividend yield of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. is 0.3%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096)?
The net margin of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. is −13.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096)?
The return on equity (ROE) of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. is −2.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096)?
On an EBIT basis the return on assets of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. is 3.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096)?
The operating margin of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. is 7.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096)?
Revenue at Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. is growing +24.6% versus a year earlier (3y avg +3.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096)?
Earnings per share at Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. are growing −56.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096) generate?
The free cash flow of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. is −253M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096) carry?
The net debt of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. is 408M CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. in the live analysis
One click puts Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
